Mantle Cell Lymphoma | Specialty

Dr. Hamlin on Next Steps With Ibrutinib/Buparlisib in MCL, FL, and DLBCL

August 21st 2017

Paul A. Hamlin, MD, of Memorial Sloan Kettering Cancer Center, discusses the next steps following a phase I dose-escalation study of buparlisib plus ibrutinib (Imbruvica) in patients with mantle cell lymphoma (MCL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL).

Dr. Martin on Potential of Immunotherapy in MCL Landscape

August 18th 2017

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the potential of modern immunotherapies in the landscape of mantle cell lymphoma (MCL).

Dr. Nowakowski on Biological Heterogeneity in Newly Diagnosed Patients With MCL

August 16th 2017

Grzegorz S. Nowakowski, MD, assistant professor of medicine at Mayo Clinic, discusses the desire to use biological heterogeneity as a factor for treatment in newly diagnosed patients with mantle cell lymphoma (MCL).

Dr. Ansell on Difficult Challenges in the MCL Landscape

August 15th 2017

Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses difficult challenges to overcome in the landscape of mantle cell lymphoma (MCL).

Dr. Shah on Options for Ibrutinib-Intolerant Patients With MCL

August 11th 2017

Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses a therapeutic option on the horizon for patients with mantle cell lymphoma (MCL) who are intolerant to ibrutinib (Imbruvica).

Higher Bortezomib Doses Linked to Longer OS in MCL

August 10th 2017

Patients with newly diagnosed mantle cell lymphoma assigned to frontline chemotherapy had a survival advantage when they were able to receiver higher dose intensities of bortezomib (Velcade).

Dr. Hamlin on Toxicities Associated With Ibrutinib and Buparlisib in MCL, FL, and DLBCL

August 10th 2017

Paul A. Hamlin, MD, of Memorial Sloan Kettering Cancer Center, discusses the toxicities reported in a phase I dose-escalation study of buparlisib plus ibrutinib (Imbruvica) in patients with mantle cell lymphoma (MCL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL).

Dr. Martin on ASCT-Related Toxicities for Patients With MCL

August 8th 2017

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the toxicities related to stem cell transplantation for patients with mantle cell lymphoma (MCL).

MRD Associated With Poorer Survival Following ASCT in MCL

August 7th 2017

Long-term results from the Nordic MCL2 and MCL3 trials showed patients with mantle cell lymphoma who are positive for minimal residual disease following allogenic stem cell transplant had significantly shorter survival.

Dr. Leonard on Exciting Advancements in the Field of Mantle Cell Lymphoma

August 7th 2017

John P. Leonard, MD, professor of Medicine at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses some of the exciting advancements taking place in the field of mantle cell lymphoma (MCL).

FDA Awards Acalabrutinib Priority Review in MCL

August 2nd 2017

The FDA has granted a priority review to a new drug application for acalabrutinib for patients with previously-treated mantle cell lymphoma.

FDA Grants Acalabrutinib Breakthrough Designation in MCL

August 2nd 2017

The FDA has granted acalabrutinib a breakthrough therapy designation for patients with previously-treated mantle cell lymphoma.

Dr. Nowakowski on the Potential Role of Immunotherapy in MCL

August 1st 2017

Grzegorz S. Nowakowski, MD, assistant professor of medicine at Mayo Clinic, discusses what potential immunotherapy agents have in the treatment landscape of mantle cell lymphoma (MCL).

Emerging Agents for Mantle Cell Lymphoma

July 26th 2017

Acalabrutinib for Treating Mantle Cell Lymphoma

July 26th 2017

Ongoing Challenges in Treating Mantle Cell Lymphoma

July 26th 2017

Treating Relapsed/Refractory Mantle Cell Lymphoma

July 26th 2017

Role of Maintenance Therapy in Mantle Cell Lymphoma

July 26th 2017

Response Assessment in Mantle Cell Lymphoma

July 26th 2017

Options for Upfront Therapy in MCL

July 26th 2017